Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2020 08/11/2020 08/12/2020 08/13/2020 08/14/2020 Date
68.51(c) 68.1(c) 68.84(c) 68.18(c) 68.5(c) Last
10 278 040 10 236 935 9 121 195 7 468 088 9 130 721 Volume
-1.21% -0.60% +1.09% -0.96% +0.47% Change
More quotes
Financials (USD)
Sales 2020 24 071 M - -
Net income 2020 2 800 M - -
Net Debt 2020 11,6 M - -
P/E ratio 2020 37,2x
Yield 2020 3,95%
Sales 2021 24 185 M - -
Net income 2021 7 824 M - -
Net cash position 2021 1 708 M - -
P/E ratio 2021 11,6x
Yield 2021 4,23%
Capitalization 85 880 M 85 880 M -
EV / Sales 2020 3,57x
EV / Sales 2021 3,48x
Nbr of Employees 11 800
Free-Float 99,5%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
More about the company
Surperformance© ratings of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
Toute l'actualité sur GILEAD SCIENCES, INC.
08/13Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
RE
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Truvad..
AQ
08/11Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
RE
08/11GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
AQ
08/11India's shortage of remdesivir is easing, says producer Cipla
RE
08/11GILEAD SCIENCES : Truvada Approved in China for Preventative HIV Use
DJ
08/11GILEAD SCIENCES : China National Medical Products Administration Approves Truvad..
BU
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10GILEAD SCIENCES : Files for FDA OK for Covid-19 Treatment Veklury
DJ
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10GILEAD SCIENCES : files U.S. marketing application for remdesivir
RE
08/10GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
BU
08/10PFIZER : Announces Agreement with Gilead to Manufacture Remdesivir for Treatment..
AQ
More news
News in other languages on GILEAD SCIENCES, INC.
08/13Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Truvad..
08/11Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
08/11GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
08/11India's shortage of remdesivir is easing, says producer Cipla
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Stock Trading Strategies
GILEAD SCIENCES - 02/03
Volatility should make a big comeback
BUY
More Stock Trading Analysis
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 80,13 $
Last Close Price 68,50 $
Spread / Highest target 41,6%
Spread / Average Target 17,0%
Spread / Lowest Target -9,49%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.5.42%85 880
VERTEX PHARMACEUTICALS22.08%69 620
REGENERON PHARMACEUTICALS63.14%64 461
WUXI APPTEC CO., LTD.63.95%36 608
GENMAB A/S55.72%23 949
BEIGENE, LTD.27.12%19 069